Get to know our clinical trials

A randomized, open-label, multicenter phase 3 clinical trial of xaluritamig in combination with abiraterone versus the investigator's choice of treatment in participants with prostate cancer.

Imagen del Dr. José Luis Pérez Gracia, especialista en Oncología Médica de la Clínica Universidad de Navarra. El Dr. Pérez Gracia se dedica preferencialmente a los tumores urológicos.
Dr. José Luis Pérez Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Prostate Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 3 STUDY OF XALURITAMIG IN COMBINATION WITH ABIRATERONE VERSUS INVESTIGATOR'S CHOICE OF TREATMENT IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY.
  • Code EudraCT: 2025-520555-89
  • Protocol number: 20230239
  • Promoter: Amgen, S.A.
  • Molecule/Drug: Xaluritamig

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION